177 related articles for article (PubMed ID: 37704613)
21. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
22. Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial.
Xu X; Fan Z; Wang Y; Huang F; Xu Y; Sun J; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Chen Y; Tu S; Huang X; Liu Q; Xuan L
BMC Med; 2022 Sep; 20(1):282. PubMed ID: 36050712
[TBL] [Abstract][Full Text] [Related]
23. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
[TBL] [Abstract][Full Text] [Related]
24. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.
Chen F; Sun J; Yin C; Cheng J; Ni J; Jiang L; Wang Q; Yu G; Wei Y; Liu X; Sun J; Carter BZ; Jiang X
Bone Marrow Transplant; 2020 Apr; 55(4):740-748. PubMed ID: 31645666
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.
Oran B; Cortes J; Beitinjaneh A; Chen HC; de Lima M; Patel K; Ravandi F; Wang X; Brandt M; Andersson BS; Ciurea S; Santos FP; de Padua Silva L; Shpall EJ; Champlin RE; Kantarjian H; Borthakur G
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1218-1226. PubMed ID: 27058617
[TBL] [Abstract][Full Text] [Related]
26. [Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Pei RZ; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):552-557. PubMed ID: 30122013
[No Abstract] [Full Text] [Related]
27. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio
Pollard JA; Alonzo TA; Gerbing R; Brown P; Fox E; Choi J; Fisher B; Hirsch B; Kahwash S; Getz K; Levine J; Brodersen LE; Loken MR; Raimondi S; Tarlock K; Wood A; Sung L; Kolb EA; Gamis A; Meshinchi S; Aplenc R
J Clin Oncol; 2022 Jun; 40(18):2023-2035. PubMed ID: 35349331
[TBL] [Abstract][Full Text] [Related]
29. Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation.
Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Kumar R; Minden MD; Chang H
Biol Blood Marrow Transplant; 2020 Nov; 26(11):1995-2000. PubMed ID: 32712325
[TBL] [Abstract][Full Text] [Related]
30. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.
Al Hamed R; Labopin M; Daguindau E; Niittyvuopio R; Huynh A; Socié G; Srour M; Henri Bourhis J; Kröger N; Tholouli E; Choi G; Poiré X; Martin H; Rubio MT; Jindra P; Blaise D; Beelen D; Labussière-Wallet H; Nagler A; Bazarbachi A; Mohty M
Cancer Med; 2022 Feb; 11(4):1068-1080. PubMed ID: 35048553
[TBL] [Abstract][Full Text] [Related]
31. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
[TBL] [Abstract][Full Text] [Related]
32. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
Battipaglia G; Massoud R; Ahmed SO; Legrand O; El Cheikh J; Youniss R; Aljurf M; Mohty M; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):506-508. PubMed ID: 31122828
[TBL] [Abstract][Full Text] [Related]
34. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Döhner K; Thiede C; Jahn N; Panina E; Gambietz A; Larson RA; Prior TW; Marcucci G; Jones D; Krauter J; Heuser M; Voso MT; Ottone T; Nomdedeu JF; Mandrekar SJ; Klisovic RB; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Jansen JH; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Benner A; Pallaud C; Stone RM; Döhner H; Bloomfield CD
Blood; 2020 Jan; 135(5):371-380. PubMed ID: 31826241
[TBL] [Abstract][Full Text] [Related]
35. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
[TBL] [Abstract][Full Text] [Related]
36. A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
Pratz KW; Rudek MA; Smith BD; Karp J; Gojo I; Dezern A; Jones RJ; Greer J; Gocke C; Baer MR; Duong VH; Rosner G; Zahurak M; Wright JJ; Emadi A; Levis M;
Biol Blood Marrow Transplant; 2020 Feb; 26(2):300-306. PubMed ID: 31550496
[TBL] [Abstract][Full Text] [Related]
37. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Tarlock K; Chang B; Cooper T; Gross T; Gupta S; Neudorf S; Adlard K; Ho PA; McGoldrick S; Watt T; Templeman T; Sisler I; Garee A; Thomson B; Woolfrey A; Estey E; Meshinchi S; Pollard JA
Pediatr Blood Cancer; 2015 Jun; 62(6):1048-54. PubMed ID: 25662999
[TBL] [Abstract][Full Text] [Related]
39. Maintenance therapy for
Burchert A
Haematologica; 2021 Mar; 106(3):664-670. PubMed ID: 33472354
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Mathew NR; Baumgartner F; Braun L; O'Sullivan D; Thomas S; Waterhouse M; Müller TA; Hanke K; Taromi S; Apostolova P; Illert AL; Melchinger W; Duquesne S; Schmitt-Graeff A; Osswald L; Yan KL; Weber A; Tugues S; Spath S; Pfeifer D; Follo M; Claus R; Lübbert M; Rummelt C; Bertz H; Wäsch R; Haag J; Schmidts A; Schultheiss M; Bettinger D; Thimme R; Ullrich E; Tanriver Y; Vuong GL; Arnold R; Hemmati P; Wolf D; Ditschkowski M; Jilg C; Wilhelm K; Leiber C; Gerull S; Halter J; Lengerke C; Pabst T; Schroeder T; Kobbe G; Rösler W; Doostkam S; Meckel S; Stabla K; Metzelder SK; Halbach S; Brummer T; Hu Z; Dengjel J; Hackanson B; Schmid C; Holtick U; Scheid C; Spyridonidis A; Stölzel F; Ordemann R; Müller LP; Sicre-de-Fontbrune F; Ihorst G; Kuball J; Ehlert JE; Feger D; Wagner EM; Cahn JY; Schnell J; Kuchenbauer F; Bunjes D; Chakraverty R; Richardson S; Gill S; Kröger N; Ayuk F; Vago L; Ciceri F; Müller AM; Kondo T; Teshima T; Klaeger S; Kuster B; Kim DDH; Weisdorf D; van der Velden W; Dörfel D; Bethge W; Hilgendorf I; Hochhaus A; Andrieux G; Börries M; Busch H; Magenau J; Reddy P; Labopin M; Antin JH; Henden AS; Hill GR; Kennedy GA; Bar M; Sarma A; McLornan D; Mufti G; Oran B; Rezvani K; Shah O; Negrin RS; Nagler A; Prinz M; Burchert A; Neubauer A; Beelen D; Mackensen A; von Bubnoff N; Herr W; Becher B; Socié G; Caligiuri MA; Ruggiero E; Bonini C; Häcker G; Duyster J; Finke J; Pearce E; Blazar BR; Zeiser R
Nat Med; 2018 Mar; 24(3):282-291. PubMed ID: 29431743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
